HomeCompareSBSAA vs JNJ

SBSAA vs JNJ: Dividend Comparison 2026

SBSAA yields 1250.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBSAA wins by $2.90M in total portfolio value
10 years
SBSAA
SBSAA
● Live price
1250.00%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.93M
Annual income
$18,066.38
Full SBSAA calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SBSAA vs JNJ

📍 SBSAA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSBSAAJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SBSAA + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SBSAA pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SBSAA
Annual income on $10K today (after 15% tax)
$106,250.00/yr
After 10yr DRIP, annual income (after tax)
$15,356.42/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SBSAA beats the other by $11,370.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SBSAA + JNJ for your $10,000?

SBSAA: 50%JNJ: 50%
100% JNJ50/50100% SBSAA
Portfolio after 10yr
$1.48M
Annual income
$11,377.89/yr
Blended yield
0.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SBSAA
No analyst data
Altman Z
-1.6
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SBSAA buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSBSAAJNJ
Forward yield1250.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$2.93M$30.3K
Annual income after 10y$18,066.38$4,689.40
Total dividends collected$1.98M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SBSAA vs JNJ ($10,000, DRIP)

YearSBSAA PortfolioSBSAA Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$73,200$62,500.00$10,592$272.30+$62.6KSBSAA
2$292,109$213,785.05$11,289$357.73+$280.8KSBSAA
3$711,212$398,655.24$12,123$472.89+$699.1KSBSAA
4$1,214,560$453,563.11$13,141$629.86+$1.20MSBSAA
5$1,661,525$361,946.06$14,408$846.81+$1.65MSBSAA
6$2,009,208$231,375.87$16,021$1,151.60+$1.99MSBSAA
7$2,280,596$130,744.14$18,122$1,588.22+$2.26MSBSAA
8$2,509,586$69,347.70$20,930$2,228.20+$2.49MSBSAA
9$2,720,916$35,659.22$24,792$3,191.91+$2.70MSBSAA
10$2,929,447$18,066.38$30,274$4,689.40+$2.90MSBSAA

SBSAA vs JNJ: Complete Analysis 2026

SBSAAStock

Spanish Broadcasting System, Inc. operates as a Spanish-language media and entertainment company in the United States. It operates in two segments, Radio and Television. The company produces and distributes Spanish-language content, including radio programs, television shows, and music and live entertainment. It also owns and operates 18 radio stations in the Los Angeles, New York, Puerto Rico, Chicago, Miami, and San Francisco markets; AIRE radio networks with approximately 290 affiliate radio stations; and 5 television stations under the MegaTV brand, as well as has various MegaTV broadcasting outlets under affiliation or programming agreements. In addition, the company produces live concerts and events; and owns bilingual websites, including lamusica.com, Mega.tv, and various station websites that provide content related to Latin music, entertainment, news, and culture, as well as operates the LaMusica mobile app; and HitzMaker, a talent destination for aspiring artists. Further, it offers Tropical, Regional Mexican, Spanish Adult Contemporary, Top 40, and Urbano format genres through its radio stations; and television programs range from televised radio-branded shows to general entertainment programs, such as music, celebrity, news, debate, interviews, and personality-based shows. The company was founded in 1983 and is based in Miami, Florida.

Full SBSAA Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SBSAA vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SBSAA vs SCHDSBSAA vs JEPISBSAA vs OSBSAA vs KOSBSAA vs MAINSBSAA vs ABBVSBSAA vs MRKSBSAA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.